Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in the early stages of the disease, today’s treatment paradigm is suboptimal owing to the considerable pill burden, a risk of motor and nonmotor complications associated with dopaminergic therapy, and a progressive loss of efficacy. In response, the pipeline for adjunctive therapies targeting motor fluctuations has swelled. With the recent launches of Xadago and Ongentys and with Nouriast and tozadenant in late-phase development, understanding the drivers of clinical decision-making for treating motor fluctuations and prescriber perceptions of approved options will help innovators identify levers for new product positioning and differentiation in this evolving market niche.
- What are the treatment drivers and goals for motor fluctuations in PD?
- What attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for motor fluctuations in PD?
- What are the prevailing areas of unmet need and opportunity in the treatment of motor fluctuations in PD?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new adjunctive drug for the treatment of motor fluctuations in PD?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European neurologists fielded in February 2017
Key companies: Teva, UCB, Newron, Zambon, US WorldMeds, Bial, Neurocrine, Kyowa Hakko Kirin, Acorda
Key drugs: oral dopamine agonists, rotigotine (Neupro), rasagiline (Azilect), selegiline, safinamide (Xadago), entacapone, Ongentys (opicapone), tozadenant, Nouriast (istradefylline)